Moderna, Inc. (MRNA) stock
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)
Close on Nov 17, 2026Market cap $82.56BP/E –Yield –
Moderna cash
Cash and short-term investments held at the end of each period.
Moderna's cash was $5.14B at Jun 30, 2026. For fiscal 2025 it was $5.80B, down 17.5% from the year before. Over ten years it grew 43.3% a year on average. The highest annual figure on record is $10.74B in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.80B | -17.5% |
| FY2024 | Dec 31, 2024 | $7.03B | -18.3% |
| FY2023 | Dec 31, 2023 | $8.60B | -13.2% |
| FY2022 | Dec 31, 2022 | $9.91B | -7.7% |
| FY2021 | Dec 31, 2021 | $10.74B | +132.4% |
| FY2020 | Dec 31, 2020 | $4.62B | +314.3% |
| FY2019 | Dec 31, 2019 | $1.12B | -27.3% |
| FY2018 | Dec 31, 2018 | $1.53B | +99.4% |
| FY2017 | Dec 31, 2017 | $768.78M | +1148.8% |
| FY2016 | Dec 31, 2016 | $61.56M | -61.3% |
| FY2015 | Dec 31, 2015 | $159.04M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.14B | +0.1% |
| Q1 FY2026 | Mar 31, 2026 | $5.21B | -12.9% |
| Q4 FY2025 | Dec 31, 2025 | $5.80B | -17.5% |
| Q3 FY2025 | Sep 30, 2025 | $4.50B | -34.4% |
| Q2 FY2025 | Jun 30, 2025 | $5.13B | -39.5% |
| Q1 FY2025 | Mar 31, 2025 | $5.98B | -29.9% |
| Q4 FY2024 | Dec 31, 2024 | $7.03B | -18.3% |
| Q3 FY2024 | Sep 30, 2024 | $6.87B | -9.3% |
| Q2 FY2024 | Jun 30, 2024 | $8.49B | +0.3% |
| Q1 FY2024 | Mar 31, 2024 | $8.52B | -4.5% |
| Q4 FY2023 | Dec 31, 2023 | $8.60B | -13.2% |
| Q3 FY2023 | Sep 30, 2023 | $7.57B | -9.3% |
| Q2 FY2023 | Jun 30, 2023 | $8.46B | +7.1% |
| Q1 FY2023 | Mar 31, 2023 | $8.92B | -11.8% |
| Q4 FY2022 | Dec 31, 2022 | $9.91B | -7.7% |
| Q3 FY2022 | Sep 30, 2022 | $8.35B | -6.3% |
| Q2 FY2022 | Jun 30, 2022 | $7.90B | -1.2% |
| Q1 FY2022 | Mar 31, 2022 | $10.12B | +30.8% |
| Q4 FY2021 | Dec 31, 2021 | $10.74B | +132.4% |
| Q3 FY2021 | Sep 30, 2021 | $8.91B | +171.8% |
| Q2 FY2021 | Jun 30, 2021 | $7.99B | +194.0% |
| Q1 FY2021 | Mar 31, 2021 | $7.74B | +535.1% |
| Q4 FY2020 | Dec 31, 2020 | $4.62B | +314.3% |
| Q3 FY2020 | Sep 30, 2020 | $3.28B | +209.6% |
| Q2 FY2020 | Jun 30, 2020 | $2.72B | +153.9% |
| Q1 FY2020 | Mar 31, 2020 | $1.22B | +9.8% |
| Q4 FY2019 | Dec 31, 2019 | $1.12B | -27.3% |
| Q3 FY2019 | Sep 30, 2019 | $1.06B | +533.6% |
| Q2 FY2019 | Jun 30, 2019 | $1.07B | +661.2% |
| Q1 FY2019 | Mar 31, 2019 | $1.11B | +1125.6% |
| Q4 FY2018 | Dec 31, 2018 | $1.53B | +99.4% |
| Q3 FY2018 | Sep 30, 2018 | $167.06M | +171.4% |
| Q2 FY2018 | Jun 30, 2018 | $140.62M | -11.6% |
| Q1 FY2018 | Mar 31, 2018 | $90.48M | – |
| Q4 FY2017 | Dec 31, 2017 | $768.78M | – |
| Q4 FY2016 | Dec 31, 2016 | $61.56M | – |
| Q4 FY2015 | Dec 31, 2015 | $159.04M | – |
See a number that looks wrong?